We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Dechra Pharmaceuticals Plc | LSE:DPH | London | Ordinary Share | GB0009633180 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3,866.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMDPH
RNS Number : 7719Z
Dechra Pharmaceuticals PLC
22 September 2020
22 September 2020
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
LEI: 213800J4UVB5OWG8VX82
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
The Company announces that on 22 September 2020 the following Directors were granted awards over Ordinary Shares of 1 pence each in the Company under the Dechra 2017 Long Term Incentive Plan:
Hot Features
Premium
Name of individual Director Type of award Number of shares
subject to award
LTIP Award -
Ian Page* Director nil cost option 32,128
---------- ------------------ ------------------
LTIP Award -
Paul Sandland Director nil cost option 13,901
---------- ------------------ ------------------
LTIP Award -
conditional
Tony Griffin Director award 10,303
---------- ------------------ ------------------
* Ian Page has also been granted a tax qualifying option over 926 shares at an exercise price of GBP32.37 as part of his LTIP award. This tax qualifying option is linked to the nil cost option such that, at the time of exercise, to the extent that there is a gain in the tax qualifying option, the nil cost option will be forfeited to the value of that gain.
The vesting of all the above awards is subject to the achievement of performance targets. In respect of these grants the performance conditions will be determined by reference to the Company's Earnings per Share (EPS) and its Total Shareholder Return (TSR) relative to constituent companies of the FTSE 250 index (excluding investment trusts) over a three year performance period. Both the EPS and TSR elements will be subject to an additional Return on Capital Employed (ROCE) performance condition. If the ROCE performance condition is not met, then the LTIP Awards will lapse in full.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Forms
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
----------------------------- -----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a) Position/status Director
----------------------------- -----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
----------------------------- -----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
----------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument ISIN: GB0009633180
Identification
code
----------------------------- -----------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan
----------------------------- -----------------------------------------
c) Price(s) and volumes(s) Nil cost option
Price Volume
Nil cost award 32,128
-------
Tax qualifying option
Price Volume
GBP32.37 (per Ordinary
Share exercise price) 926
-------
----------------------------- -----------------------------------------
d) Aggregated information
* Aggregate volume
Awards granted over 33,054 Ordinary
Shares in total
* Price N/A
----------------------------- -----------------------------------------
e) Date of the transaction 2020-09-22
----------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------- -----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
----------------------------- -----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a) Position/status Director
----------------------------- -----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
----------------------------- -----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
----------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument ISIN: GB0009633180
Identification
code
----------------------------- -----------------------------------------
b) Nature of the Grant of an award over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan
----------------------------- -----------------------------------------
c) Price(s) and volumes(s) Nil cost option
Price Volume
Nil cost award 13,901
-------
----------------------------- -----------------------------------------
d) Aggregated information
* Aggregate volume
N/A
* Price
----------------------------- -----------------------------------------
e) Date of the transaction 2020-09-22
----------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------- -----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Tony Griffin
----------------------------- -----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a) Position/status Director
----------------------------- -----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
----------------------------- -----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
----------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument ISIN: GB0009633180
Identification
code
----------------------------- -----------------------------------------
b) Nature of the Grant of an award over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan
----------------------------- -----------------------------------------
c) Price(s) and volumes(s) Conditional award
Price Volume
Nil cost award 10,303
-------
----------------------------- -----------------------------------------
d) Aggregated information
* Aggregate volume
N/A
* Price
----------------------------- -----------------------------------------
e) Date of the transaction 2020-09-22
----------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------- -----------------------------------------
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharm aceuticals PLC.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHKKBBPQBKDCCB
(END) Dow Jones Newswires
September 22, 2020 11:00 ET (15:00 GMT)
1 Year Dechra Pharmaceuticals Chart |
1 Month Dechra Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
